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Weighing in on malaria-attributable low birthweight 
in Africa
Imagine providing care for 900 000 low birthweight 
(LBW; lighter than 2500 g) newborn babies each year 
in sub-Saharan Africa—all attributable to preventable 
and treatable malaria. Many of these LBW babies will be 
born in rural and impoverished settings where access 
to health care is poorest and the risk of complicating 
factors, including other infectious diseases and under-
nutrition, is most pronounced. This scenario, with the 
caveat that no malaria prevention services are provided, 
is the sobering estimate of malaria-attributable LBW for 
2010 provided by Patrick Walker and colleagues1 in this 
issue of The Lancet Global Health. Prevention services 
are provided in many places, but present coverage of 
these services in sub-Saharan African countries is poor, 
with 22% of the population estimated to have received 
intermittent preventive treatment and 39% having 
used insecticide-treated mosquito nets (ITNs).2 Walker 
and colleagues are likely to follow soon with updated 
modelled estimates for the beneﬁ t achieved with these 
preventive actions and the remaining LBW burden still 
to be addressed.
The long and costly care for LBW infants is daunting 
enough for families and health services, but the increased 
LBW-associated risk of neonatal and infant death is 
especially concerning.3 Because LBW is the consequence 
of prematurity, intrauterine growth retardation (IUGR), 
or a combination, and because the risk of infant mortality 
diﬀ ers and is substantially higher for premature newborn 
babies compared with term-IUGR newborn babies,4,5 we 
cannot directly translate this LBW estimate into an infant 
mortality estimate. Unfortunately, malaria infection 
during pregnancy contributes to both prematurity 
and IUGR,6,7 and thus the associated mortality risk is 
substantial. Again, because relevant data exist, hopefully 
Walker and colleagues (or others) can also provide 
estimates for the mortality risk both with and without 
interventions in sub-Saharan Africa and build on the 
existing estimates.8
Some suspicion always surrounds modelled estimates of 
health outcomes. However, the methods used here include 
the key components of known biology and immunology 
and draw attention to crucial issues9—that young women 
and those in their ﬁ rst pregnancy are especially at risk, 
that immunity develops with repeated exposure during 
pregnancies, and that the likelihood of detection of 
infection is highest at the ﬁ rst antenatal clinic visit because 
of the cumulative untreated infections before and during 
pregnancy until the ﬁ rst visit. Walker and colleagues point 
out that prevention in young women of reproductive 
age is an important opportunity not presently targeted 
by malaria programmes or antenatal clinic programmes. 
Teenagers are the age group least likely to use malaria 
prevention interventions such as ITNs, and typically have 
the highest malaria infection rates.10 The pre-pregnancy 
period is also increasingly recognised as important, 
but challenging for other conditions and interventions 
including immunisations for measles, rubella, hepatitis, 
meningitis, tetanus, human papillomavirus,11 and, of 
course, family planning. Malaria programmes should add 
their voice to the eﬀ orts to reach these young women, and, 
as service delivery methods improve through schools or 
other means, malaria detection and treatment followed 
by ongoing malaria prevention should be a core part of the 
service in malaria-endemic settings.
An additional opportunity exists because of this 
cumulative acquisition of malaria infection that might be 
diagnosed at the ﬁ rst antenatal clinic visit, especially in 
ﬁ rst pregnancies. Some African country programmes are 
embarking on elimination and seek to identify and clear 
all malaria infections in all age groups, including women 
of reproductive age and pregnant women. This presents 
an excellent opportunity to end malaria-attributable 
prematurity, IUGR, and LBW, and the health risks to 
the mother and her newborn baby. However, with this 
cumulative interval of potential infection, the pregnant 
women might carry some of the remaining infections that 
are occurring in the population. The typical high rates of 
antenatal clinic attendance by pregnant women in Africa 
can aid their inclusion in an important surveillance eﬀ ort 
in which malaria testing in women at ﬁ rst antenatal clinic 
visit can show either residual infection in the population 
or absence of infection that might be an indicator that 
elimination is imminent or has been achieved. Finally, 
under such elimination eﬀ orts, surveillance in these 
highest risk populations must persist, because any 
residual infections in these women can be deadly.
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